Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PC-18
- Development stage
- Discontinued
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PC-18 is a standardized dry purified extract derived from the plant *Paullinia cupana*. It was investigated in two double-blind randomized clinical trials for its potential to alleviate chemotherapy-induced fatigue in early breast cancer patients. The studies compared oral doses of PC-18 (37.5 mg twice daily, or 7.5 mg/12.5 mg twice daily) against a placebo. The trials concluded that PC-18 was not superior to placebo, possibly due to an unexpectedly high antifatigue activity observed in the placebo group, which was correlated with increased magnesium levels. No significant toxicities were observed in the trials.
- Other names
- Purified Dry Paullinia cupana Extract
Beyond the preview
Go deeper on PC-18.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PC-18.